Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts

Zhen Song; Qi Zhou; Jiang-Lei Zhang; Jun Ouyang; Zhi-Yu Zhang

doi:10.12998/wjcc.v12.i1.32

Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts

World J Clin Cases. 2024 Jan 6;12(1):32-41. doi: 10.12998/wjcc.v12.i1.32.

Authors

Zhen Song^{1

2}, Qi Zhou³, Jiang-Lei Zhang², Jun Ouyang², Zhi-Yu Zhang⁴

Affiliations

¹ Department of Urology, Taixing People's Hospital, Taizhou 225400, Jiangsu Province, China.
² Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
³ Department of Reproductive Medicine Center, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
⁴ Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China. abner_666@126.com.

Abstract

Background: Prostate cancer (PCa) is a widespread malignancy, predominantly affecting elderly males, and current methods for diagnosis and treatment of this disease continue to fall short. The marker Ki-67 (MKI67) has been previously demonstrated to correlate with the proliferation and metastasis of various cancer cells, including those of PCa. Hence, verifying the association between MKI67 and the diagnosis and prognosis of PCa, using bioinformatics databases and clinical data analysis, carries significant clinical implications.

Aim: To explore the diagnostic and prognostic efficacy of antigens identified by MKI67 expression in PCa.

Methods: For cohort 1, the efficacy of MKI67 diagnosis was evaluated using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. For cohort 2, the diagnostic and prognostic power of MKI67 expression was further validated using data from 271 patients with clinical PCa.

Results: In cohort 1, MKI67 expression was correlated with prostate-specific antigen (PSA), Gleason Score, T stage, and N stage. The receiver operating characteristic (ROC) curve showed a strong diagnostic ability, and the Kaplan-Meier method demonstrated that MKI67 expression was negatively associated with the progression-free interval (PFI). The time-ROC curve displayed a weak prognostic capability for MKI67 expression in PCa. In cohort 2, MKI67 expression was significantly related to the Gleason Score, T stage, and N stage; however, it was negatively associated with the PFI. The time-ROC curve revealed the stronger prognostic capability of MKI67 in patients with PCa. Multivariate COX regression analysis was performed to select risk factors, including PSA level, N stage, and MKI67 expression. A nomogram was established to predict the 3-year PFI.

Conclusion: MKI67 expression was positively associated with the Gleason Score, T stage, and N stage and showed a strong diagnostic and prognostic ability in PCa.

Keywords: Biomarker; Diagnosis; Marker Ki-67; Prognosis; Prostate cancer.